IMAC Holdings, Inc. Stock: price and management transactions · United States · SEC (Form 4)Follow the IMAC Holdings, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, IMAC Holdings, Inc. has recorded 32 reports. Market capitalisation: €756. The latest transaction was reported on 18 March 2025 (Cession). Among the most active insiders: Evans Maurice E.. The full history is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 18 March 2025
All Executives32 Thresholds0 Prospectus0 Other0
Declarations 32 total
5,000 shares @ US$3.00 2.5% of flow Common stock SEC:0002060450-25-000006:0
1 shares @ US$2.69 0.0% of flow Common stock SEC:0002060450-25-000007:0
Canonical exit: 4 Jul 2024 (T+90) 100 shares @ US$2.415 0.0% of flow Common stock SEC:0002060450-25-000004:0
164,872 shares @ €3.2955 97.5% of flow Common stock SEC:0002060450-25-000003:0
Canonical exit: 20 Jun 2024 (T+90) ◆ Director · Executives · 31 Dec 2024
3,333 shares Common Stock, no par value SEC:0001493152-25-000073:0
◆ Director · Executives · 31 Dec 2024
3,333 shares Common Stock, no par value SEC:0001493152-25-000071:0
◆ Director · Executives · 31 Dec 2024
3,333 shares Common Stock, no par value SEC:0001493152-25-000070:0
◆ Director · Executives · 31 Dec 2024
3,333 shares Common Stock, no par value SEC:0001493152-25-000074:0
◆ Director · Executives · 31 Dec 2024
3,333 shares Common Stock, no par value SEC:0001493152-25-000072:0
◇ Director · Executives · 20 Dec 2023
3,333 shares Common Stock SEC:0000921895-23-002801:0
◇ Director · Executives · 20 Dec 2023
3,333 shares Common Stock SEC:0000921895-23-002802:0
◇ Director · Executives · 20 Dec 2023
3,333 shares Common Stock SEC:0000921895-23-002803:0
◆ Director · Executives · 15 Oct 2022
100,000 shares 0Common Stock SEC:0001493152-22-029220:0
◆ Director · Executives · 15 Oct 2022
100,000 shares 0Common Stock SEC:0001493152-22-029221:0
◆ Director · Executives · 15 Oct 2022
100,000 shares 0Common Stock SEC:0001493152-22-029219:0
◇ Chief Financial Officer · Executives · 21 May 2022
9,375 shares Common Stock SEC:0001493152-22-015056:0
◇ Chief Executive Officer · Executives · 21 May 2022
37,500 shares Common Stock SEC:0001493152-22-015054:0
◆ Chief Operating Officer · Executives · 21 Feb 2022
100,000 shares 0Common Stock SEC:0001493152-22-005275:0
◇ Director · Executives · 1 Jan 2022
50,000 shares Common Stock SEC:0001493152-22-000613:0
◇ Director · Executives · 1 Jan 2022
50,000 shares Common Stock SEC:0001493152-22-000615:0
◇ Director · Executives · 1 Jan 2022
50,000 shares Common Stock SEC:0001493152-22-000614:0
◇ Director · Executives · 1 Nov 2021
12,500 shares Common Stock SEC:0001493152-21-027095:0
◇ Director · Executives · 1 Nov 2021
12,500 shares Common Stock SEC:0001493152-21-027096:0
◇ Director · Executives · 1 Nov 2021
12,500 shares Common Stock SEC:0001493152-21-027094:0
◇ Director · Executives · 1 Aug 2021
12,500 shares Common Stock SEC:0001493152-21-022749:0
25 of 32 declarations
Load more (7 remaining) 关于 IMAC Holdings, Inc. IMAC Holdings, Inc.(股票代码:BACK)是一家在美国纳斯达克市场上市的美国公司,历史定位专注于骨科治疗、康复和微创手术等专业医疗保健服务。该公司最初是肯塔基州有限责任公司 IMAC Holdings, LLC,并于2018年6月1日正式转变为特拉华州公司 IMAC Holdings, Inc.。其主要行政办公室位于田纳西州富兰克林。([sec.gov](https://www.sec.gov/Archives/edgar/data/1729944/000149315223010385/form10-k.htm?utm_source=openai))
从商业模式的角度来看,美国证券交易委员会(SEC)的文件显示,IMAC曾作为多家业务线的控股公司运营,包括IMAC再生中心、BackSpace零售/诊所网点以及一个试验性新药部门。历史上,该公司专注于保守、非侵入性或微创治疗,用于治疗背痛、膝痛、关节痛、韧带和肌腱损伤以及其他软组织疾病。其披露文件还提及与知名体育人物的合作,这反映了其在运动医学和以表现为导向的护理领域建立品牌知名度和可信度的努力。([sec.gov](https://www.sec.gov/Archives/edgar/data/1729944/000149315219005467/form10-k.htm?utm_source=openai))
尽管如此,近期运营历史表明公司进行了重大的战略调整。SEC文件指出,2023年公司决定停止与表现不佳的诊所网点和BackSpace零售店相关的业务活动。换句话说,IMAC一直在收缩和简化其业务范围,而非扩张。对于投资者而言,这是一个重要信号:公司故事不再是关于快速开设诊所,而是关于重组、流动性管理和保留选择权。([sec.gov](https://www.sec.gov/Archives/edgar/data/1729944/000149315224019793/form10-q.htm?utm_source=openai))
竞争定位最好在美国高度分散的医疗保健市场背景下审视。IMAC的历史竞争对手包括独立的骨科诊所、门诊康复服务提供商、运动医学诊所和门诊护理集团。该公司的差异化主张是一种非阿片类、以功能为中心的治疗模式。然而,其规模小、反复重组和财务压力意味着它应被视为投机性微型股,而非稳定的、规模化的医疗保健平台。([sec.gov](https://www.sec.gov/Archives/edgar/data/1729944/000149315222009946/form10-k.htm?utm_source=openai))
近期发展进一步证实了这一结论。在2025年和2026年,IMAC进行了多项与债务相关的交易,包括期票和有担保融资安排,反映了持续的流动性需求。SEC文件还提及涉及有担保票据和债权人协议的重组步骤。因此,对于法国、比利时和瑞士投资者而言,BACK需要谨慎解读:它是一家在纳斯达克上市的美国医疗保健公司,运营可见度非常有限,财务风险较高,并且对SEC披露文件高度依赖以进行任何有意义的评估。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001729944/000149315225029639/form8-k.htm?utm_source=openai))